Dear Registered Shareholder(s), 10 October 2025 BOCOM International Holdings Company Limited (the "Company") - Extraordinary General Meeting ("EGM") of the Company to be held on Wednesday, 5 November 2025 The EGM will be held at Conference Room 1, 9/F, Man Yee Building, 68 Des Voeux Road Central, Hong Kong and online through online platform on Wednesday, 5 November 2025 at 3:00 p.m.. The EGM will be a hybrid meeting. Shareholders have the option of attending, participating and voting in the EGM through the ...

N O T I F I C AT I O N L E T T E R 通 知 信 函 Dear Non-registered Shareholders(Note 1) , BOCOM International Holdings Company Limited (the "Company") – Publication of the Circular dated 10 October 2025 containing Notice of Extraordinary General Meeting (the "Current Corporate Communications") The Current Corporate Communications of the Company have been published in English and Chinese languages and are available on the Company's website at www.bocomgroup.com and the HKEXnews's website at www.hkexnews.hk. If y ...

N O T I F I C AT I O N L E T T E R 通 知 信 函 10 October 2025 Dear Registered Shareholders, BOCOM International Holdings Company Limited (the "Company") – Publication of the Circular dated 10 October 2025 containing Notice of Extraordinary General Meeting together with Proxy Form (the "Current Corporate Communications") The Current Corporate Communications of the Company have been published in English and Chinese languages and are available on the Company's website at www.bocomgroup.com and the HKEXnews's webs ...

BOCOM INTERNATIONAL HOLDINGS COMPANY LIMITED （股份代號：3329） 於2025年11月5日（星期三）舉行之股東特別大會及其任何續會之代表委任表格 本人╱吾等 （附註1） 地址為 為交銀國際控股有限公司（「本公司」） 股普通股的登記持有人 （附註2） ， 茲委任大會主席或 地址為 （於香港註冊成立的有限公司） 日期： 簽署： （附註5） 附註： 8. 本代表委任表格之任何變更，均須由簽署人簡簽示可。 個人信息收集聲明 （附註3） 1. 請用正楷填上全名及登記在本公司股東名冊上之股東地址。 2. 請填上以 閣下名義登記與本代表委任表格有關的股份數目。倘未有填上數目，則本代表委任表格將被視為與所有登記於 閣下名下之本公司股份有關。 3. 閣下如欲委任大會主席以外之其他人士為受委代表，請將「大會主席或」之字樣刪去，並在空欄內填上所擬委派代表之全名及地址。如未有填上姓名，則大會主席將出 任 閣下的受委代表。擁有多於一股本公司股份的股東有權委任多於一名代表出席，並於進行投票表決時代其投票。如委任多於一名代表，則必須委任每名代表以代 表該股東投票權的指定比例。受委代表毋須為本公 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本通告的內容概不負責，對其準確性或完整性亦 不發表任何聲明，並明確表示，概不對因本通告全部或任何部分內容而產生或因倚賴該等內容而引致的任 何損失承擔任何責任。 代表董事會 交銀國際控股有限公司 公司秘書 曾佳荔 謹啟 香港，2025年10月10日 BOCOM INTERNATIONAL HOLDINGS COMPANY LIMITED （於香港註冊成立的有限公司） （股份代號：3329） 股東特別大會通告 茲通告交銀國際控股有限公司（「本公司」）謹訂於 2025 年 1 1 月 5 日（星期 三）下午三時正，假座香港德輔道中68號萬宜大廈9樓1號會議室及通過網上平台 https://meetings.computershare.com/BOCOMI_2025EGM舉行股東特別大會（「股東特別 大會」），旨在考慮及酌情通過下列決議案（不論有否予以修訂）。本股東特別大會通告 未明確界定之詞彙及表達與本公司日期為2025年10月10日的通函（「該通函」）所界定者 具有相同涵義。 普通決議案 2. 本公司將於2025年10月31日（星期五）至2025年11月5日（星期 ...

Group 1 - The core viewpoint of the article highlights that QFIN Technology (QFIN.US) has seen a pre-market increase of 1.12%, reaching a price of $28.84, following a report from CCB International recommending several Chinese stocks, including QFIN Technology and Alibaba, with a "Buy" rating [1] - CCB International has set a target price of $58 for QFIN Technology, indicating a significant upside potential from its current trading price [1] - The stock's performance metrics include a closing price of $28.52, a market capitalization of $3.777 billion, and a price-to-earnings ratio of 4.92, reflecting its valuation in the market [1] Group 2 - The trading volume for QFIN Technology was reported at 1.2983 million shares, with a price range between a high of $29.09 and a low of $28.30 during the trading session [1] - The stock has a 52-week high of $46.768 and a 52-week low of $27.640, indicating its price volatility over the past year [1] - The average trading price was noted at $28.57, with a turnover rate of 1.18%, suggesting moderate trading activity [1]

此乃要件 請即處理 閣下如對本通函任何方面或應採取之行動有任何疑問，應諮詢 閣下之持牌證券交易商、註冊證券機構、銀行經理、 律師、專業會計師或其他專業顧問獲取獨立意見。 閣下如已將名下之交銀國際控股有限公司的全部股份出售或轉讓，應立即將本通函及隨附之代表委任表格送交買主或 承讓人，或經手買賣或轉讓之銀行經理、持牌證券交易商或註冊證券機構或其他代理商，以便轉交買主或承讓人。 獨立董事委員會及獨立股東之 獨立財務顧問 ALTUS CAPITAL LIMITED ቺᑼၗԖज़Ϧљ 除文義另有所指外，本封面頁所使用詞彙與本通函所界定者具有相同涵義。 董事會函件載於本通函第4頁至15頁。獨立董事委員會函件載於本通函第16頁至17頁。浩德融資有限公司函件（當中載 有其向獨立董事委員會及獨立股東提供之意見）載於本通函第18頁至30頁。 有關本公司謹訂於2025年11月5日（星期三）下午三時正假座香港德輔道中68號萬宜大廈9樓1號會議室及通過網上平台 https://meetings.computershare.com/BOCOMI_2025EGM舉行的股東特別大會之通告載於本通函第36頁至37頁。 香港交易及結算所有限公司 ...

Group 1 - The Hong Kong stock market continued its upward trend in September, driven by the resumption of US-China trade negotiations and expectations of overseas interest rate cuts, along with a rotation in the technology sector [1][2] - The external environment is showing marginal improvement, with increased market risk appetite supported by ongoing US-China trade talks and stable macro policies in mainland China [2][3] Group 2 - Liquidity pressure in Hong Kong has eased with the resumption of overseas interest rate cuts, leading to accelerated inflows of southbound capital, with a net inflow exceeding 1.1 trillion HKD this year, setting a new historical high [3] - The market is expected to enter a "quiet season" due to the National Day and Mid-Autumn Festival holidays, alongside uncertainties related to the US government's short-term financing plan, which may amplify overseas disturbances [4] Group 3 - The investment strategy continues to focus on a "high elasticity" and "high dividend" approach, with adjustments based on policy catalysts [5] - In the technology growth sector, the valuation recovery logic for tech stocks is further strengthened under the interest rate cut environment, with strong demand from southbound capital for high-growth sectors like AI [5] - The biopharmaceutical sector is expected to see valuation recovery, with Chinese innovative drug companies accelerating their global expansion [5] - High dividend yielding sectors such as banks, insurance, and utilities are highlighted as stable components in investment portfolios, providing consistent dividend income amid market volatility [5]

Core Insights - The report from CMB International highlights the release of the first batch of innovative pharmaceutical technology medical insurance payment incentive catalog by Zhejiang Province, which is expected to alleviate the challenges of innovative drugs entering hospitals [1] - Despite the Trump administration's announcement of a 100% tariff on imported innovative drugs, the overall impact on China's pharmaceutical industry chain is considered manageable, with a recommendation to monitor subsequent developments [1] - The upcoming ESMO conference in mid to late October is noted as a key event, with a focus on companies such as CanSino Biologics (09926), Kelun-Biotech (06990), and Rongchang Biologics (688331.SH) that are expected to release significant data [1] Industry Summary - The Hong Kong pharmaceutical sector has shown relatively flat performance in September, but with increasing industry catalysts such as academic conferences and favorable policy implementations in October, a market rebound is anticipated [1] - The report recommends focusing on specific segments: 1) Innovative drugs: Companies like 3SBio (01530) and Eucure Biopharma-B (06996) have rich short-term catalysts and their valuations do not yet reflect the core value of major products; companies like Ascletis Pharma (02096), Hutchison China MediTech (00013), and Legend Biotech are considered significantly undervalued with clear long-term growth logic [1] 2) CXO: Leaders in this segment, such as WuXi AppTec (02268), are expected to benefit from high downstream demand and marginal recovery in financing [1]

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 | 截至月份: | 2025年9月30日 | 狀態: 新提交 | | --- | --- | --- | | 致：香港交易及結算所有限公司 | | | | 公司名稱: | 交銀國際控股有限公司 | | | 呈交日期: | 2025年10月2日 | | | I. 法定/註冊股本變動 不適用 | | | FF301 第 1 頁 共 10 頁 v 1.1.1 FF301 II. 已發行股份及/或庫存股份變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 (註1) | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 03329 | 說明 | 不適用 | | | | | | | | 已發行股份（不包括庫存股份）數目 | | 庫存股份數目 | | 已發行股份總數 | | | 上月底結存 | | | 2,734,392,000 | | 0 | | 2,734,392,000 | | 增加 / 減少 (-) | | ...